Rasagiline News

Rasagiline currently has 3 news articles, with 20 predicted indications.

This page combines the AI-predicted indications for Rasagiline with the latest health news. Indications highlighted in orange have recent news coverage.

Drug Information

Original indication: Azilect is indicated for the treatment of idiopathic Parkinson's disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end-of-dose fluctuations.
Evidence level: L5
Predicted indications (20):
- hereditary late onset Parkinson disease (99.9%)
- juvenile onset Parkinson disease 19A (99.9%)
- X-linked parkinsonism-spasticity syndrome (99.7%)
- atypical juvenile parkinsonism (99.7%)
- PLA2G6-associated neurodegeneration (99.7%)
- Rasmussen subacute encephalitis (99.6%)
- Parkinson disease (99.4%)
- parkinsonian-pyramidal syndrome (99.3%)
- myelitis (99.3%)
- paralysis agitans, juvenile, of Hunt (99.2%)
- transaldolase deficiency (99.2%)
- hemiparkinsonism-hemiatrophy syndrome (99.2%)
- polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis (99.0%)
- congenital disorder of glycosylation with defective fucosylation (98.8%)
- Lewy body dementia (98.8%)
- fructose-1,6-bisphosphatase deficiency (98.8%)
- retinal dystrophy with or without extraocular anomalies (98.8%)
- early-onset parkinsonism-intellectual disability syndrome (98.8%)
- lethal infantile mitochondrial myopathy (98.7%)
- Charcot-Marie-Tooth disease, demyelinating, type 1G (98.7%)